Several mid-market biotech companies are showing promise with targeted cancer therapies-treatments, as discussed most recently at the 2014 American Society of Clinical Oncologists (ASCO) annual meeting at McCormick Place in Chicago from May 30-June 3.

This new class of cancer immunotherapies are known for going directly after the cause of the malignancies in patients. The approach differs from more traditional oncology regimens, such as chemotherapy, which kill fast-dividing cells indiscriminatley while seeking to shrink tumors. With these innovative drugs passing muster in clinical trials, companies including Epizyme Inc. (Nasdaq: EPZM) are drawing the attention of acquisitive biopharmaceutical players eager to bring new medicines to market.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.